Even if CD8+ TILs and PD-L1 expression are associated with worse survival, as our data indicate, SNSCCs appear to be immunogenic tumors where immunotherapy may present a new possibility for the treatment of this aggressive type of cancer. This evidence concerns the gene CD8A and cancer.